Pesticides and Parkinson's disease

Biomedicine and Pharmacotherapy

Volumn 53, Issue 3, 1999, Pages 122-130

  Le Couteur, D G ^a   McLean, A J ^b   Taylor, M C ^a   Woodham, B L ^a   Board, P G ^a  

^a Molecular Genetics Group   (Australia)

^b Biology and Environment   (Australia)

Author keywords

Aging; Parkinson's disease; Pesticide

Indexed keywords

NEUROTOXIN; PESTICIDE;

ENVIRONMENTAL EXPOSURE; GENETIC POLYMORPHISM; HUMAN; MITOCHONDRION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; XENOBIOTIC METABOLISM;

EID: 0033117146     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80077-8     Document Type: Article

References (117)

1. 1 Abernathy CO, Hodgson E, Guthrie FE. Structure-activity relationships on the induction of hepatic microsomal enzymes in the mouse by 1,1,1 -trichloro-2,2-bisp-(chlorophenyl)ethane (DDT) analogs. Biochem Pharmacol 1971 ; 20 : 2385-93.
2. 2 Anadon A, Martinez-Larranaga MR, Diaz MJ, Bringas P, Fernandez MC, Martinez MA, et al. Effects of flumethrin on hepatic drug-metabolizing enzymes and antipyrine disposition in rats. Toxicol Appl Pharmacol 1995 ; 132 : 14-8.
3. 3 Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylase genes in Parkinson's disease. Lancet 1992 ; 339 : 1017-8.
4. 4 Bandmann O, Marsden CD, Wood NW. Genetic aspects of Parkinson's disease. Mov Disord 1998 ; 13 : 203-11.
5. 5 Barbeau A. Etiology of Parkinson's disease: a research strategy. Can J Neurol Sci 1984 ; 11 : 24-8.
6. 6 Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985 ; ii : 1213-6.
7. 7 Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 1987 ; 14 : 36-41.
8. 8 Barbeau A, Roy M, Langston JW. Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Lancet 1985 ; i : 747.
9. 9 Bell IR, Schwartz GE, Amend D, Peterson JM, Kasniak AW, Miller CS. Psychological characteristics and subjective intolerance for xenobiotic agents of normal young adults and trait shyness and defensiveness. J Nerv Ment Disord 1994 ; 7 : 367-74.
10. 10 Berger CW, Sultatos LG. The effects of the phosphorothioate insecticide fenitrothion on mammalian cytochrome P450-dependent metabolism of estradiol. Fund Appl Toxicol 1997 ; 37 : 150-7.
11. 11 Bocchetta A, Corsini GU. Parkinson's disease and pesticides. Lancet 1986 ; ii : 1163.
12. 12 Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1985 ; 312 : 1418-21.
13. 13 Bus JS, Cagen SZ, Olgaard M, Gibson JE. A mechanism of paraquat toxicity in mice and rats. Toxicol Appl Pharmacol 1976 ; 35 : 501-3.
14. 14 Butler AM, Murray M. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J Pharmacol Exp Ther 1997 ; 280 : 966-73.
15. 15 Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993 ; 43 : 1150-8.
16. 16 Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983 ; ii : 1457-9.
17. 17 Chan DKY, Woo J, Ho SC, Pang CP, Law LK, Ng PW, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998 ; 65 : 781-4.
18. 18 Chapman LJ, Sauter SL, Henning RA, Levine RL, Matthews CG, Peters HA. Finger tremor after carbon disulfide-based pesticide exposures. Arch Neurol 1991 ; 48 : 866-70.
19. 19 Cocco P, Blair A, Congia P, Saba G, Ecca AR, Palmas C. Long-term health effects of the occupational exposure to DDT. Ann NY Acad Sci 1997 ; 837 : 246-56.
20. 20 Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 -implications for Parkinson's disease. J Pharmacol Exp Ther 1996 ; 277 : 685-90.
21. 21 Collins MA. Potential parkinsonian protoxicants within and without. Neurobiol Ageing 1994; 15: 277-8.
22. 22 Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psych Res 1979; 1: 249-54.
23. 23 Davis KL, Yesavage JA, Berger PA. Single case study. Possible organophosphate-induced parkinsonism. J Nerv Ment Disord 1978; 166: 222-5.
24. 24 Davis MW, Le Couteur DG, Webb M, Board PG. Multidrug resistance associated protein, p-glycoprotein and Parkinson's disease. Aust NZ J Med 1998; 28: 491.
25. 25 Desole MS, Esposito G, Enrico P, Miele M, Fresu L, De Natale G, et al. Effects of ageing on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat. Neurosci Lett 1993; 159: 143-6.
26. 26 Di Ilio C, Sacchetta P, Angelucci S, Bucciarelli T, Pennelli A, Mazzetti AP, et al. Interaction of glutathione transferase P1-1 with captan and captofol. Biochem Pharmacol 1996; 52: 43-8.
27. 27 Dubey RK, Beg MU, Singh J. Effects of endosulfan and its metabolites on rat liver mitochondrial respiration and enzyme activities in vitro. Biochem Pharmacol 1984; 33: 3405-10.
28. 28 Duvoisin RC. A brief history of parkinsonism. Neurol Clin 1992; 10: 301-16.
29. 29 Ecobichon DJ, Joy RM. Pesticides and Neurological Diseases. (2nd ed.) Boca Raton: CRC Press; 1994.
30. 30 Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J. In: Ellenhorn's Medical Toxicology. (2nd ed.). Baltimore: The Williams & Wilkins Company; 1997.
31. 31 Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidum, but not in the substantia nigra. Brain Res 1997; 753: 157-62.
32. 32 Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994; 36: 100-3.
33. 33 Furlong CE, Li WF, Costa LG, Richter RJ, Shih DM, Lusis AJ. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism. Neurotoxicology 1998; 19: 645-50.
34. 34 Gassner B, Wuthrich A, Scholtysik G, Solioz M. The pyrethroids permethrin and cyhalothrin are potent inhibitors of the mitochondrial complex I. J Pharmacol Exp Ther 1997; 28: 855-60.
35. 35 Golbe LI. Parkinson's disease: nature meets nuture. Lancet 1998; 352: 1328-9.
36. 36 Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990; 5: 66-70.
37. 37 Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water and rural living. Neurology 1998; 50: 1346-50.
38. 38 Gourie-Devi M, Ramu MG, Venkataram BS. Treatment of Parkinson's disease in 'Ayurveda' (ancient Indian system of medicine): discussion paper. J Roy Soc Med 1991; 84: 491-2.
39. 39 Hart TB. Parkinson's disease and pesticides. Lancet 1987; ii: 38.
40. 40 Hayes WJ. In: Toxicology of Pesticides. Baltimore: The Williams & Wilkins Company, 1975.
41. 41 Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, et al. Diet and Parkinson's disease II: a possible role for the past intake of specific nutrients. Neurology 1996; 47: 644-50.
42. 42 Herishanu YO, Kordysh E, Goldsmith JR. A case-referent study of extrapyramidal signs (preparkinsonism) in rural communities of Israel. Can J Neurol Sci 1998; 25: 127-33.
43. 43 Hertzman C, Wiens M, Bowering E, Snow B, Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Indust Med 1990; 17: 349-55.
44. 44 Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 1994; 9: 69-75.
45. 45 Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology 1989; 39: 1314-8.
46. 46 Hodgson E, Levi PE. Pesticides: an important but underused model for the environmental health sciences. Environ Health Perspect 1996; 104: 97-106.
47. 47 Holmuhamedov EL, Kholmoukhamedova GL, Baimuradov TB. Non-cholinergic toxicity of organophosphates in mammals: interaction of ethaphos with mitochondrial functions. J Appl Toxicol 1996; 16: 475-81.
48. 48 Howard JK. A clinical survey of paraquat formulation workers. Br J Ind Med 1979; 36: 220-3.
49. 49 Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993; 43: 1693-7.
50. 50 Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 1993; 146 Suppl: 6-13.
51. 50 Jenner P. Altered mitochondrial function, iron metabolism andglutathione levels in Parkinson's disease. Acta Neurol Scand 1993; 146 Suppl: 6-13.
52. 51 Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344: 796-8.
53. 51 Jenner P. Oxidative damage in neurodegenerative disease.Lancet 1994; 344: 796-8.
54. 52 Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Exposure to well water and pesticides in Parkinson's disease: a case control study in Madrid area. Mov Disord 1992; 7: 149-52.
55. 53 Koller W, Vetere-Overfield B, Gray C, Alexander S, Chin T, Dolezal J, et al. Environmental risk factors in Parkinson's disease. Neurology 1990; 40: 1218-21.
56. 54 Koller WC. Paraquat and Parkinson's disease. Neurology 1986; 36: 1147.
57. 55 Kolmodin B, Azarnoff DL, Sjoquist F. Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther 1969; 10: 638-42.
58. 56 Kondo I, Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 1998; 806: 271-3.
59. 57 Langston JW. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 1998; 44 Suppl 1: 45-52.
60. 58 Langston JW. MPTP and Parkinson's disease. TINS 1985; 79-83.
61. 59 Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983; 219: 979-80.
62. 60 Langston JW, Ballard PA. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. N Engl J Med 1983; 309: 310.
63. 61 Le Couteur DG, McCann SJ. P450 enzymes and Parkinson's disease. Mov Disord 1998; 13: 851-2.
64. 62 Le Couteur DG, McLean AJ. The ageing liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-73.
65. 63 Le Couteur DG, McLean AJ, Blackburn AC, Mellick GD, Board PG. Glutathione transferase polymorphism and Parkinson's disease. Lancet 1998; 353: 71-2.
66. 64 Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997; 48: 1583-8.
67. 65 Marsden CD. Parkinson's disease. Lancet 1990; 335: 948-52.
68. 66 McCann SJ, Le Couteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinsons disease in an Australian population. Neuroepidem 1998; 17: 310-7.
69. 67 McCann SJ, Pond SM, Le Couteur DG. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control sludy and meta-analysis. J Neurol Sci 1997; 153: 50-3.
70. 68 McNaught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, et al. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 1998; 56: 921-33.
71. 69 Meco G, Bonifati V, Vanacore N, Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganse ethylene-bis-dithiocarbamate). Scand J Work Environ Health 1994; 20: 301-5.
72. 70 Meguro T, Izushi F, Ogata M. Effect of heptachlor on hepatic mitochondrial oxidative phosphorylation in rat. Ind Health 1990; 28: 151-7.
73. 71 Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couleur DG. Parkinson's disease, pesticides and glutathione transferase polymorphisms. Lancet 1998; 352: 1344-6.
74. 72 Menegon A, Board PG, Le Couteur DG, Halliday G. The immunohistochemistry of pi class glutathione transferase in the brain in Parkinson's disease. Proc ASCEPT 1998; 5: 158.
75. 73 Metzler DF. Health impact of organics in ground water. Am J Pub Health 1982; 72: 1375-84.
76. 74 Moody DE, Hammock BD. The effect of tridiphane (2-(3,5-dichlorophenyl)-2-(2,2,2-trichloroethyl)oxirane) on hepatic epoxide-metabolizing enzymes: indications of peroxisome proliferation. Toxicol Appl Pharmacol 1987; 89: 37-46.
77. 75 Moreno AJ, Madeira VM. Mitochondrial bioenergetics as affected by DDT. Biochim Biophys Acta 1991; 1060: 166-74.
78. 76 Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 1985; 36: 2503-8.
79. 77 Ogata M, Izushi F, Eto K, Sakai R, Inoue B, Noguchi N. Effect of chlordane on hepatic mitochondrial respiration. Toxicol Lett 1989; 48: 1161-6.
80. 78 O'Malley M. Clinical evaluation of pesticide exposure and poisonings. Lancet 1997; 349: 1161-6.
81. 79 Orlorunsogo OO, Babunmi EA, Bassier O. Effect of glyphosate on rat liver mitochondria in vivo. Bull Environ Cont Toxicol 1979; 22: 357-64.
82. 80 Palmeira CM, Moreno AJ, Madeira VM. Interactions of herbicides 2,4-D and dinseb with liver mitochondrial bioenergetics. Toxicol Appl Pharmacol 1994; 127: 50-7.
83. 81 Palmeira CM, Moreno AJ, Madeira VM. Mitochondrial bioenergetics is affected by the herbicide, paraquat. Biochim Biophys Acta 1995; 1229: 187-92.
84. 82 Parker VH. Effect of nitrophenols and halgenophenols on the enzymatic activity of rat liver mitochondria. Biochem J 1957; 69: 306-10.
85. 83 Parkinson J. An essay on the shaking palsy. London/Sherwood: Neely and Jones; 1817.
86. 84 Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Trans 1997; 104: 661-7.
87. 85 Peters RA. Lethal synthesis. Proc Roy Soc Lond 1952; 13: 139-43.
88. 86 Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs. Lancet 1987; ii: 386.
89. 87 Przedborski S, Jackson-Lewis V. Mechanisms fo MPTP toxicity. Mov Disord 1998; 13 Suppl 1: 35-8.
90. 87 Przedborski S, Jackson-Lewis V. Mechanisms fo MPTP toxicity. Mov Disord 1998; 13 Suppl 1: 35-8.
91. 88 Sanchez-Ramos J, Song S, Facca A, Basil A. Dieldrin an dopamine neuron toxicity. Neurology 1995; 45 Suppl 4: A379.
92. 88 Sanchez-Ramos J, Song S, Facca A, Basil A. Dieldrin andopamine neuron toxicity. Neurology 1995; 45 Suppl 4: A379.
93. 89 Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology 1987; 37: 728.
94. 90 Sechi GP, Agnetti V, Piredda M, Canu M, Deserra F, Omar HA, et al. Acute and persistent parkinsonism after use of diquat. Neurology 1992; 42: 261-3.
95. 91 Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, et al. Possible environmental, occupational, and other etiological factors for Parkinson's disease: a case-control study in Germany. Neurology 1996; 46: 1275-84.
96. 92 Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agriculture work and pesticide chemicals. Neurology 1992; 42: 1328-35.
97. 93 Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991; 30: 332-9.
98. 94 Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 1998; 19: 709-12.
99. 95 Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-7.
100. 96 Snyder SH, D'Amato RJ. Predicting Parkinson's disease. Nature 1985; 317: 198-9.
101. 97 Sotaniemi EA, Arranto AJ, Pelkonen O, Fasanen M. Age and cytochrome P450-lonked drug metabolism in humans: an analysis of 226 subjects with equal histopathological conditions. Clin Pharmacol Ther 1997; 61: 331-9.
102. 98 Stem M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, et al. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch Neurol 1991; 48: 903-7.
103. 99 Sutherland JM. Parkinson's diseas: aetiological factors and certain clincal features. Aust NZ J Med 1971; Suppl 1: 29-34.
104. 100 Suzuki T, Fujita S, Narimatsu S, Masubuchi Y, Tachibana M, Ohta S, et al. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J 1992; 6: 771-6.
105. 101 Tanner CM. Influence of environmental factors on the onset of Parkinson's disease. Neurology 1986; 36 Suppl 1: 215.
106. 102 Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 1989; 12: 49-54.
107. 103 Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X, et al. Environmental factors and Parkinson's disease: a case control study in China. Neurology 1989; 39: 660-4.
108. 104 Taylor M, Board PG, Mellick GD, Le Couteur DG. Paraoxonase (PON1 and PON2) polymorphisms and Parkinson's disease. Proc ASCEPT 1998; 5: 160.
109. 105 Uitti RJ, Snow BJ, Shinotoh H, Vingerhoets FJ, Hayward M, Hashimoto S, et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994; 35: 616-9.
110. 106 Vieregge P. Genetic factors in the etiology of idiopathic Parkinson's disease. J Neural Trans 1994; 8: 1-37.
111. 107 Vizuete ML, Merino M, Cano J, Machado A. In vivo protection of striatal dopaminergic system against 1-methyl-4-methylpyridinium neurotoxicity by phenobarbital. J Neurosci Res 1997; 49: 301-8.
112. 108 Waring RH, Sturman SG, Smith MCG, Steventon GB, Heafield MTE, Williams AC. S-methylation in motor neuron disease and Parkinson's disease. Lancet 1989; 356-7.
113. 109 Way JL. Cyanide intoxication and its mechanism of antagonism. Annu Rev Pharmacol Toxicol 1984; 24: 451-81.
114. 110 Wechsler LS, Checkoway H, Franklin GM, Costa LG. A pilot study of occupational and environmental risk factors for Parkinson's disease. Neurotoxicology 1991; 12: 387-92.
115. 111 Williams A. Hypersusceptibility to chemicals: risk factors for neurological disease? J Neurol Neurosurg Psychiatr 1993; 56: 943-6.
116. 112 Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991; 48: 287-9.
117. 113 Woodrooffe AJM, Bayliss MK, Park GR. The effects of hypoxia on drug-metabolizing enzymes. Drug Metab Rev 1995; 27: 471-95.